Effects of recombinant drug-specific single chain antibody Fv fragment on [3H]-desipramine distribution in rats

Biochemical Pharmacology

Volumn 51, Issue 4, 1996, Pages 531-537

  Shelver, Weilin L ^a   Keyler, Daniel E ^a,e   Lin, Gaofeng ^b   Murtaugh, Michael P ^b   Flickinger, Michael C ^c   Ross, Catherine A ^a   Pentel, Paul R ^a,d  

^a HENNEPIN COUNTY MEDICAL CENTER   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Antibody; Immunotherapy; Immunotoxicology; Overdose; SFv fragment; Tricyclic antidepressant

Indexed keywords

ANTIDOTE; BOVINE SERUM ALBUMIN; DESIPRAMINE; DRUG ANTIBODY; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN FRAGMENT; IMMUNOGLOBULIN G; RADIOISOTOPE; RECOMBINANT IMMUNOGLOBULIN FV FRAGMENT; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIBODY BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EXCRETION; DRUG OVERDOSE; DRUG SPECIFICITY; DRUG URINE LEVEL; IMMUNOTHERAPY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANALYSIS OF VARIANCE; ANIMALS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; BINDING SITES; DESIPRAMINE; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOGLOBULIN FRAGMENTS; IMMUNOGLOBULIN VARIABLE REGION; MALE; METABOLIC CLEARANCE RATE; RADIOISOTOPE DILUTION TECHNIQUE; RATS; RECOMBINANT PROTEINS; TRITIUM;

EID: 0030030677     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-2952(95)02233-3     Document Type: Article

References (32)

1. Smith TW, Review of clinical experience with digoxin immune Fab (ovine). Am J Emerg Med 9(Suppl 1): 1-6, 1991.
2. Ochs HR and Smith TW, Reversal of advanced digitoxin toxicity and modification of pharmacokinetics by specific antibodies and Fab fragments. J Clin Invest 60: 1303-1313, 1977.
3. Baud FJ, Sabouraud A, Vicaut E, Taboulet P, Lang J, Bismuth C, Rouzioux JM and Scherrmann J-M, Brief report: Treatment of severe colchicine overdose with colchicine-specific Fab fragments. New Engl Med 332: 642-645, 1995.
4. McClurkan MB, Valentine JL, Arnold L and Owens SM, Disposition of a monoclonal anti-phencyclidine Fab fragment of immunoglobulin G in rats. J Pharmacol Exp Ther 266: 1439-1445, 1993.
5. Chen H, Bowles MR and Pond SM, Prevention of paraquat toxicity in suspensions of alveolar type II cells by paraquat-specific antibodies. Hum Exp Toxicol 13: 551-557, 1994.
6. Brunn GJ, Keyler DE, Pond SM and Pentel PR, Reversal of desipramine toxicity in rats using drug-specific antibody Fab' fragment: Effects on hypotension and interaction with sodium bicarbonate. J Pharmacol Exp Ther 260: 1392-1399, 1991.
7. Smith TW, Lloyd BL, Spicer H and Haber E, Immunogenicity and kinetics of distribution and elimination of sheep digoxin-specific IgG and Fab fragments in the rabbit and baboon. Clin Exp Immunol 36: 384-396, 1979.
8. Keyler DE, Salerno DM, Murakami MM, Ruth G and Pentel PR, Rapid administration of high-dose human antibody Fab fragments to dogs: Pharmacokinetics and toxicity. Fundam Appl Toxicol 17: 83-91, 1991.
9. Pentel PR, Ross CA, London J, Sidki A, Shelver WL and Keyler DE, Reversal of desipramine toxicity in rats using polyclonal drug-specific antibody Fab fragments. J Lab Clin Med 123: 387-393, 1994.
10. Keyler DE, Shelver WL, Landon J, Sidki A and Pentel PR, Toxicity of high doses of polyclonal drug specific antibody Fab fragments, Int J Immunopharmacol 16: 1027-1034, 1994.
11. Lloyd BL and Smith TW, Contrasting rates of reversal of digoxin toxicity by digoxin-speciftc IgG and Fab fragments. Circulation 58: 280-283, 1978.
12. Hochman J, Inbar D and Givol D, An active antibody fragment (Fv) composed of the variable portions of heavy and light chains. Biochemistry 12: 1130-1135, 1973.
13. Huston JS, Levinson D, Mudgett-Hunter M, Tai MS, Novotny J, Margolies MN, Tidge RJ, Bruccoleri RE, Haber E, Crea R and Oppermann H, Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analog produced in Escherichia coli. Proc Natl Acad Sci USA 85: 5879-5883, 1988.
14. Bird RE, Hardman KD, Jacobson JW, Johnson S, Kaufman GM, Lee SM, Lee T, Pope SH, Riordan GS and Whitlow M, Singlechain antigen-binding proteins. Science 242: 423-426, 1988.
15. Huston JS, McCartney J, Tai MS, Mottola-Hartshorn C, Jin D, Warren F, Keck P and Oppermann H, Medical applications of single-chain antibodies. Int Rev Immunol 10: 195-217, 1993.
16. Colcher D, Bird R, Roselli M, Hardman KD, Johnson S, Pope S, Dodd SW, Pantoliano MW, Milenic DE and Schlom J, In vivo tumor targeting of a recombinant single-chain antigen-binding protein. J Natl Cancer Inst 82: 1191-1197, 1990.
17. Milenic DE, Yokota T, Filpula DR, Finkelman MAJ, Dodd SW, Wood JF, Whitlow M, Snoy P and Schlom J, Construction, binding properties, metabolism, and tumor targeting of a singlechain Fv derived from the pancarcinoma monoclonal antibody CC49. Cancer Res 51: 6363-6371, 1991.
18. Laroche Y, Demaeyer M, Stassen JM, Gansemans Y, Demarsin E, Matthyssens G, Collen D and Holvoet P, Characterization of a recombinant single-chain molecule comprising the variable domains of a monoclonal antibody specific for human fibrin fragment D-dimer. J Biol Chem 266: 16343-16349, 1991.
19. Litovitz TL, Clark LR and Soloway RA, 1993 Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 12: 546-584, 1994.
20. Moran RJ, Struthers AD and Hewick DS, Digoxin-specific Fab fragments impair renal function in the rat. J Pharm Pharmacol 46: 854-856, 1994.
21. Kitchin K, Lin G, Shelver WL, Murtaugh MP, Pentel PR, Pond SM, Janelle CO, Humphrey JE, Smith JM and Flickinger MC, Cloning, expression and purification of an anti-desipramine single chain antibody in NS/0 myeloma cells. J Pharm Sci 84: 1184-1189, 1995.
22. Bowles M, Johnston SC, Schoof DD, Pentel PR and Pond SM, Large scale production and purification of paraquat and desipramine monoclonal antibodies and their Fab fragments, Int J Immunopharmacol 10: 537-545, 1988.
23. Hogg PJ, Johnston SC, Bowles MR, Pond SM and Winzor DJ, Evaluation of equilibrium constants for antigen-antibody interactions by solid-phase immunoassay: The binding of paraquat to its elicited mouse monoclonal antibody. Mol Immunol 24: 797-801, 1987.
24. Bradford MM, A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding. Anal Biochem 72: 248-254, 1976.
25. Pentel PR and Keyler DE, Effects of high dose alpha-1-acid glycoprotein on desipramine toxicity in rats. J Pharmacol Exp Ther 246: 1061-1066, 1988.
26. McCartney JE, Lederman L, Drier EA, Cabral-Denison NA, Wu GM, Batorsky RS, Huston JS and Oppermann H, Biosynthetic antibody binding sites: Development of a single-chain Fv model based on antidinitrophenol IgA myeloma MOPC 315. J Prot Chem 10: 669-683, 1991.
27. DeVane CL, Simpkins JW and Stout SA, Cerebral and blood pharmacokinetics of imipramine and its active metabolites in the pregnant rat. Psychopharmacology 84: 225-232, 1984.
28. Pentel PR, Keyler DE, Brunn GJ, Milavetz JM, Gilbertson DG, Matta SG and Pond SM, Redistribution of tricyclic antidepressants in rats using a drug-specific monoclonal antibody: Dose -response relationship. Drug Metab Dispos 19: 24-28, 1991.
29. Pentel PR, Brunn GJ, Pond SM and Keyler DE, Pretreatment with drug-specific antibody reduces desipramine cardiotoxicity in rats. Life Sci 48: 675-683, 1991.
30. Keyler DE, Le Couteur DG, Pond SM, St. Peter JV and Pentel PR, Effects of specific antibody Fab fragments on desipramine pharmacokinetics in the rat in vivo and in the isolated perfused liver. J Pharmacol Exp Ther 272: 1117-1123, 1995.
31. Glockshuber R, Malia M, Pftizinger I and Pluckthun A, A comparison of strategies to stabilize immunoglobulin Fv-fragments. Biochemistry 29: 1362-1367, 1990.
32. Brinkmann U, Reiter Y, Jung S, Lee B and Pastan I, A recombinant immunotoxin containing a disulfide-stabilized Fv fragment. Proc Natl Acad Sci USA 90: 7538-7542, 1993.